Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B : estimates from a European network of hospitals

Rondy, Marc ; Launay, Odile ; Puig-Barbera, Joan ; Gefenaite, Giedre LU orcid ; Castilla, Jesús ; de Gaetano Donati, K ; Galtier, F. ; Hak, Eelko ; Guevara, M and Costanzo, Simona , et al. (2015) In Eurosurveillance 20(2).
Abstract

While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls.... (More)

While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
contributor
Lenzi, Nezha and Olivieri, Marco
publishing date
type
Contribution to journal
publication status
published
in
Eurosurveillance
volume
20
issue
2
article number
21011
publisher
European Centre for Disease Prevention and Control (ECDC)
external identifiers
  • pmid:25613779
  • scopus:84926507200
ISSN
1560-7917
DOI
10.2807/1560-7917.ES2015.20.2.21011
project
Infectious diseases surveillance, vaccine effectiveness and determinants of acceptance
language
English
LU publication?
no
id
b2f0b5d3-0d2b-48dc-be04-dea5b6060243
date added to LUP
2023-02-02 10:39:56
date last changed
2024-02-02 08:35:31
@article{b2f0b5d3-0d2b-48dc-be04-dea5b6060243,
  abstract     = {{<p>While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H<sub>1</sub>N<sub>1</sub>)pdm09, 58 for A(H<sub>3</sub>N<sub>2</sub>) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H<sub>1</sub>N<sub>1</sub>) pdm09, A(H<sub>3</sub>N<sub>2</sub>) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H<sub>3</sub>N<sub>2</sub>) and B and low against influenza A(H<sub>1</sub>N<sub>1</sub>) pdm09.</p>}},
  author       = {{Rondy, Marc and Launay, Odile and Puig-Barbera, Joan and Gefenaite, Giedre and Castilla, Jesús and de Gaetano Donati, K and Galtier, F. and Hak, Eelko and Guevara, M and Costanzo, Simona and Collective European hospital IVE network and Moren, Alain}},
  issn         = {{1560-7917}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{2}},
  publisher    = {{European Centre for Disease Prevention and Control (ECDC)}},
  series       = {{Eurosurveillance}},
  title        = {{2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B : estimates from a European network of hospitals}},
  url          = {{http://dx.doi.org/10.2807/1560-7917.ES2015.20.2.21011}},
  doi          = {{10.2807/1560-7917.ES2015.20.2.21011}},
  volume       = {{20}},
  year         = {{2015}},
}